Oxford University begins human trials for new Ebola vaccine targeting Bundibugyo strain

Researchers at the University of Oxford have initiated human clinical trials for a new Ebola vaccine, ChAdOx BDBV, designed to target the Bundibugyo ebolavirus strain. This experimental vaccine utilizes the same adaptable chimpanzee adenovirus vector platform as the Oxford-AstraZeneca COVID-19 vaccine. The trial aims to assess the vaccine's safety and its ability to stimulate an immune response in 50 healthy adult volunteers, addressing a critical gap in preparedness as the existing licensed Ebola vaccine, Ervebo, is ineffective against this particular strain currently causing an outbreak in the Democratic Republic of Congo. AI

RANK_REASON Initiation of human clinical trials for a new vaccine candidate. [lever_c_demoted from research: ic=1 ai=0.0]

Read on Forbes — Innovation →

• Bundibugyo ebolavirus
• ChAdOx BDBV
• COVID-19
• Democratic Republic of Congo
• Ervebo
• Oxford Vaccine Group
• Pandemic Sciences Institute
• University of Oxford
• World Health Organization
• Zaire ebolavirus

• paper
• product
• other

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →